A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma

Ipilimumab (IPI) can enhance immunity to the cancer-testis antigen NY-ESO-1. A clinical trial was designed to assess safety, immunogenicity, and clinical responses with IPI + NY-ESO-1 vaccines and effects on the tumor microenvironment (TME). Patients with measurable NY-ESO-1(+) tumors were enrolled...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncoimmunology
Glavni autori: Slingluff, Craig L., Zarour, Hassane M., Tawbi, Hussein Abdul-Hassan, Kirkwood, John M., Postow, Michael A., Friedlander, Philip, Devoe, Craig E., Gaughan, Elizabeth M., Mauldin, Ileana S., Olson, Walter C., Smith, Kelly T., Macri, Mary J., Ricciardi, Toni, Ryan, Aileen, Venhaus, Ralph, Wolchok, Jedd D.
Format: Artigo
Jezik:Inglês
Izdano: Taylor & Francis 2021
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8007150/
https://ncbi.nlm.nih.gov/pubmed/33796406
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2021.1898105
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items